HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road?

Publication date: Available online 31 October 2018Source: European Journal of Surgical OncologyAuthor(s): Wim CeelenAbstractIn patients with colorectal peritoneal metastases (PM), the use of cytoreductive surgery (CRS) and HIPEC with oxaliplatin (OX) is increasingly used. The results of the recently reported randomized Prodige 7 trial failed to show a difference in overall survival between patients undergoing CRS alone versus CRS combined with HIPEC using high dose OX. The trial was not designed or powered, however, to detect a potentially clinically meaningful benefit in locoregional disease control. Here, I address some potential explanations for the lack of benefit in the Prodige 7 trial, including OX efficacy issues, adverse effects of intraperitoneal high dose glucose, and potential drawbacks of the use of hyperthermia.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research